This rash is most common with targeted therapies that block a protein called EGFR (epidermal growth factor receptor), which helps keep skin healthy. These treatments include:
- Tyrosine kinase inhibitors (TKIs): erlotinib, afatinib, dacomitinib, osimertinib, lapatinib, gefitinib
- Monoclonal antibodies: cetuximab, necitumumab, pertuzumab, panitumumab
- MEK inhibitors (used for melanoma): trametinib, binimetinib, cobimetinib
Up to 90% of patients may develop this rash, usually within the first few days or weeks of starting treatment. In some cases, the rash can become severe and even infected, especially by bacteria. Interestingly, having a rash may be a sign that the treatment is working well.
Why Do Targeted Therapies Cause This Rash?
Acne-like rash is a common side effect of certain cancer treatments that target specific skin pathways, such as EGFR or MEK. These treatments can disrupt normal skin function, causing inflammation and weakening the skin’s natural defenses. This makes it easier for bacteria to grow, leading to infection.
The rash usually appears on areas with more oil glands, like the face, scalp, chest, and upper back, because these spots are more sensitive and prone to inflammation.
Let me know if you'd like this adapted for a handout, translated, or paired with care tips.